{"id":"lv5fu2-or-capecitabine","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Hand-foot skin reaction (palmar-plantar erythrodysesthesia)"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"20-30","effect":"Nausea and vomiting"},{"rate":"20-30","effect":"Fatigue"},{"rate":"10-20","effect":"Stomatitis"},{"rate":"5-15","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"10-15","effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) that is preferentially activated in tumor tissue by thymidine phosphorylase. Once activated, it inhibits thymidylate synthase, blocking dTMP synthesis and preventing DNA replication, while also incorporating into RNA to disrupt protein synthesis. LV5FU2 refers to the combination of leucovorin (folinic acid) with 5-FU, where leucovorin enhances 5-FU efficacy by stabilizing the thymidylate synthase-FdUMP complex.","oneSentence":"LV5FU2/capecitabine is a fluoropyrimidine prodrug that inhibits thymidylate synthase and gets incorporated into DNA/RNA, disrupting cancer cell replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:37.266Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (metastatic and adjuvant settings)"},{"name":"Gastric cancer"},{"name":"Breast cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT03217097","phase":"NA","title":"MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-10-16","conditions":"Neuroendocrine Tumors","enrollment":116},{"nctId":"NCT03828227","phase":"PHASE3","title":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2019-06-14","conditions":"Elderly Patients, Metastatic Colorectal Cancer, Quality of Life","enrollment":49},{"nctId":"NCT04257461","phase":"PHASE3","title":"A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma","status":"UNKNOWN","sponsor":"Belgian Group of Digestive Oncology","startDate":"2020-02-20","conditions":"Small Bowel Adenocarcinoma","enrollment":30},{"nctId":"NCT03117972","phase":"PHASE2","title":"Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2017-08-04","conditions":"Metastatic Colorectal Cancer","enrollment":54},{"nctId":"NCT05476796","phase":"PHASE2","title":"Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2023-06-23","conditions":"Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":118},{"nctId":"NCT02842580","phase":"PHASE2","title":"De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-09","conditions":"Colorectal Neoplasms","enrollment":21},{"nctId":"NCT02355379","phase":"PHASE3","title":"Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2015-01","conditions":"Colonic Adenocarcinoma","enrollment":774},{"nctId":"NCT03351296","phase":"PHASE2","title":"Two Chemotherapy Regimens Plus or Minus Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-06-26","conditions":"Pancreatic Cancer","enrollment":140},{"nctId":"NCT04188145","phase":"PHASE3","title":"A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-01-27","conditions":"Metastatic Colorectal Cancer","enrollment":400},{"nctId":"NCT01802684","phase":"PHASE2","title":"OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-05","conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9273,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LV5FU2 or capecitabine","genericName":"LV5FU2 or capecitabine","companyName":"Federation Francophone de Cancerologie Digestive","companyId":"federation-francophone-de-cancerologie-digestive","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LV5FU2/capecitabine is a fluoropyrimidine prodrug that inhibits thymidylate synthase and gets incorporated into DNA/RNA, disrupting cancer cell replication. Used for Colorectal cancer (metastatic and adjuvant settings), Gastric cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}